BrainStorm Announces Clinical Data from NurOwn Trial

The data from the initial patients in its ALS Phase I/II human clinical trial treated with its NurOwn? technology did not present any significant side effects and that the NurOwn? treatment has so far proven to be safe.

BrainStorm Cell Therapeutics Inc. has announced that the data from the initial patients in its ALS Phase I/II human clinical trial treated with its NurOwn? technology did not present any significant side effects and that the NurOwn? treatment has so far proven to be safe.

Prof. Dimitrios Karussis, who is leading the clinical trial at Hadassah Medical Center, stated, “There have been no significant side effects in the initial patients we have treated with BrainStorm’s NurOwn? technology. In addition, even though we are conducting a safety trial, the early clinical follow up of the patients treated with the stem cells shows indications of beneficial clinical effects, such as an improvement in breathing and swallowing ability as well as in muscular power. I am very excited about the safety results, as well as these indications of efficacy, we are se